Skip to main content
Erschienen in: International Urology and Nephrology 1/2009

01.03.2009 | Urology - Original Paper

The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie’s disease

verfasst von: Can Tuygun, Ugur Hakkı Ozok, Adnan Gucuk, I. Halil Bozkurt, M. Abdurrahim Imamoglu

Erschienen in: International Urology and Nephrology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Aim

To determine the effectiveness of transdermal electromotive administration (TEA) of verapamil and dexamethasone in the treatment of Peyronie’s disease (PD).

Method

Totally, 51 patients with PD were prospectively included in the study. All patients were evaluated by history, subjective score scales, physical examination, photographs, and penile USG, before and after therapy. All patients were treated with TEA of the combination of verapamil and dexamethasone. The treatment plan included a total of 20 sessions (at 3-day intervals for a period of 2 months), each with a duration of 20 min. At the end of the study, improvements in penile plaques, penile deviation, pain on erection, and erectile dysfunction were determined.

Results

The findings in 41 of the 51 patients were eligible to present. Median patient age was 52 years. Median duration of disease at presentation was 8 months. Remarkable reduction in palpable plaques and in penile angulation was observed in 10 patients (24%) and 11 (26%) patients, respectively. There were significant decreases in median plaque volume from 72 mm2 to 45 mm2 (P < 0.001), and in median penile angulation from 25º to 15º (P < 0.001). Impaired sexual activity and pain on erection had completely resolved in 11 (55%) patients and in 16 (80%), respectively.

Conclusion

The results of our study have shown that TEA of the combination of verapamil and dexamethasone is a more effective therapy for improving subjective symptoms rather than objective symptoms. Therefore, we think that this treatment can be individualized according to the clinical features of PD patients.
Literatur
1.
Zurück zum Zitat Tefekli A, Kandirali E, Erol H, Alp T, Köksal T, Kadioğlu A (2001) Peyronie’s disease in men under age 40: characteristics and outcome. Int J Impot Res 13(1):18–23PubMedCrossRef Tefekli A, Kandirali E, Erol H, Alp T, Köksal T, Kadioğlu A (2001) Peyronie’s disease in men under age 40: characteristics and outcome. Int J Impot Res 13(1):18–23PubMedCrossRef
2.
Zurück zum Zitat Mulhall JP, Creech SD, Boorjian SA (2004) Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 171(6 Pt 1):2350–2353PubMedCrossRef Mulhall JP, Creech SD, Boorjian SA (2004) Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 171(6 Pt 1):2350–2353PubMedCrossRef
3.
Zurück zum Zitat Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U (2001) The prevalence of Peyronie’s disease: results of a large survey. BJU Int 88(7):727–730PubMedCrossRef Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U (2001) The prevalence of Peyronie’s disease: results of a large survey. BJU Int 88(7):727–730PubMedCrossRef
4.
Zurück zum Zitat Hellstrom WJ, Bivalacqua TJ (2000) Peyronie’s disease: etiology, medical, and surgical therapy. J Androl 21(3):347–354PubMed Hellstrom WJ, Bivalacqua TJ (2000) Peyronie’s disease: etiology, medical, and surgical therapy. J Androl 21(3):347–354PubMed
5.
Zurück zum Zitat Devine CJ, Somers KD, Ladaga LE (1991) Peyronie’s disease: pathophysiology. Prog Clin Biol Res 370:355–358PubMed Devine CJ, Somers KD, Ladaga LE (1991) Peyronie’s disease: pathophysiology. Prog Clin Biol Res 370:355–358PubMed
6.
Zurück zum Zitat Levine LA, Merrick PF, Lee RC (1994) Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol 151(6):1522–1524PubMed Levine LA, Merrick PF, Lee RC (1994) Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol 151(6):1522–1524PubMed
7.
Zurück zum Zitat Devine CJ, Somers KD, Jordan SG, Schlossberg SM (1997) Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 157:285–290PubMedCrossRef Devine CJ, Somers KD, Jordan SG, Schlossberg SM (1997) Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 157:285–290PubMedCrossRef
8.
Zurück zum Zitat Jarow JP, Lowe FC (1997) Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 158:1388–1390PubMedCrossRef Jarow JP, Lowe FC (1997) Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 158:1388–1390PubMedCrossRef
9.
Zurück zum Zitat Van de Water L (1997) Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie’s disease. J Urol 157:306–310PubMedCrossRef Van de Water L (1997) Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie’s disease. J Urol 157:306–310PubMedCrossRef
10.
Zurück zum Zitat Bour H (1984) Current status of vitamin E. Rev Prat 34:1270–1271PubMed Bour H (1984) Current status of vitamin E. Rev Prat 34:1270–1271PubMed
11.
Zurück zum Zitat Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP (1992) The treatment of Peyronie’s disease with tamoxifen. Br J Urol 70(6):648–651PubMedCrossRef Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP (1992) The treatment of Peyronie’s disease with tamoxifen. Br J Urol 70(6):648–651PubMedCrossRef
12.
Zurück zum Zitat Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF (1994) Is colchicine effective in Peyronie’s disease? A pilot study. Urology 44(2):291–295PubMedCrossRef Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF (1994) Is colchicine effective in Peyronie’s disease? A pilot study. Urology 44(2):291–295PubMedCrossRef
13.
Zurück zum Zitat Carson CC (1997) Potassium para-aminobenzoate for the treatment of Peyronie’s disease: is it effective? Tech Urol 3:135–139PubMed Carson CC (1997) Potassium para-aminobenzoate for the treatment of Peyronie’s disease: is it effective? Tech Urol 3:135–139PubMed
14.
Zurück zum Zitat Fitkin J, Ho GT (1999) Peyronie’s disease: current management. Am Fam Physician 60(2):549–552PubMed Fitkin J, Ho GT (1999) Peyronie’s disease: current management. Am Fam Physician 60(2):549–552PubMed
15.
Zurück zum Zitat Weidner W, Hauck EW, Schnitker J (2005) Peyronie’s Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol 47(4):530–535PubMedCrossRef Weidner W, Hauck EW, Schnitker J (2005) Peyronie’s Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol 47(4):530–535PubMedCrossRef
16.
Zurück zum Zitat Gelbard MK, Dorey F, James K (1990) The natural history of Peyronie’s disease. J Urol 144:1376–1379PubMed Gelbard MK, Dorey F, James K (1990) The natural history of Peyronie’s disease. J Urol 144:1376–1379PubMed
17.
Zurück zum Zitat Tunuguntla HS (2001) Management of Peyronie’s disease—a review. World J Urol 19:244–250PubMedCrossRef Tunuguntla HS (2001) Management of Peyronie’s disease—a review. World J Urol 19:244–250PubMedCrossRef
18.
Zurück zum Zitat Levine LA (1997) Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol 158:1395–1399PubMedCrossRef Levine LA (1997) Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol 158:1395–1399PubMedCrossRef
19.
Zurück zum Zitat Rehman J, Benet A, Melman A (1998) Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology 51:620–626PubMedCrossRef Rehman J, Benet A, Melman A (1998) Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology 51:620–626PubMedCrossRef
20.
Zurück zum Zitat Levine LA, Goldman KE, Greenfield JM (2002) Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 168(2):621–625PubMedCrossRef Levine LA, Goldman KE, Greenfield JM (2002) Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 168(2):621–625PubMedCrossRef
21.
Zurück zum Zitat Hellstrom WJ, Kendirci M, Matern R (2006) Single-blind, multicenter, placebo controlled paralel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol 176(1):394–398PubMedCrossRef Hellstrom WJ, Kendirci M, Matern R (2006) Single-blind, multicenter, placebo controlled paralel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol 176(1):394–398PubMedCrossRef
22.
Zurück zum Zitat Gelbard MK, James K, Riach P, Dorey F (1993) Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol 149(1):56–58PubMed Gelbard MK, James K, Riach P, Dorey F (1993) Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol 149(1):56–58PubMed
23.
Zurück zum Zitat Ludwig G (1991) Evaluation of conservative therapeutic approaches to Peyronie’s disease (fibrotic induration of the penis). Urol Int 47(4):236–239PubMedCrossRef Ludwig G (1991) Evaluation of conservative therapeutic approaches to Peyronie’s disease (fibrotic induration of the penis). Urol Int 47(4):236–239PubMedCrossRef
24.
Zurück zum Zitat Riedl CR, Plas E, Engelhardt P, Daha K, Pflüger H (2000) Iontophoresis for treatment of Peyronie’s disease. J Urol 163(1):95–99PubMedCrossRef Riedl CR, Plas E, Engelhardt P, Daha K, Pflüger H (2000) Iontophoresis for treatment of Peyronie’s disease. J Urol 163(1):95–99PubMedCrossRef
25.
Zurück zum Zitat Montorsi F, Salonia A, Guazzoni G (2000) Transdermal electromotive multi-drug administration for Peyronie’s disease: preliminary results. J Androl 21:85–90PubMed Montorsi F, Salonia A, Guazzoni G (2000) Transdermal electromotive multi-drug administration for Peyronie’s disease: preliminary results. J Androl 21:85–90PubMed
26.
Zurück zum Zitat Di Stasi SM, Giannantoni A, Capelli G (2003) Transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. BJU Int 91:825–829PubMedCrossRef Di Stasi SM, Giannantoni A, Capelli G (2003) Transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. BJU Int 91:825–829PubMedCrossRef
27.
Zurück zum Zitat Di Stasi SM, Giannantoni A, Stephen RL (2004) A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol 171:1605–1608PubMedCrossRef Di Stasi SM, Giannantoni A, Stephen RL (2004) A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol 171:1605–1608PubMedCrossRef
28.
Zurück zum Zitat Greenfield JM, Shah SJ, Levine LA (2007) Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol 177(3):972–975PubMedCrossRef Greenfield JM, Shah SJ, Levine LA (2007) Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol 177(3):972–975PubMedCrossRef
29.
Zurück zum Zitat Mulhall JP, Anderson MS, Lubrano T, Shankey TV (2002) Peyronie’s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 14(5):397–405PubMedCrossRef Mulhall JP, Anderson MS, Lubrano T, Shankey TV (2002) Peyronie’s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 14(5):397–405PubMedCrossRef
30.
Zurück zum Zitat Martin DJ, Badwan K, Parker M, Mulhall JP (2002) Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 168(6):2483–2485PubMedCrossRef Martin DJ, Badwan K, Parker M, Mulhall JP (2002) Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 168(6):2483–2485PubMedCrossRef
31.
Zurück zum Zitat Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S (2002) A retrospective review of 307 men with Peyronie’s disease. J Urol 168(3):1075–1079PubMedCrossRef Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S (2002) A retrospective review of 307 men with Peyronie’s disease. J Urol 168(3):1075–1079PubMedCrossRef
Metadaten
Titel
The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie’s disease
verfasst von
Can Tuygun
Ugur Hakkı Ozok
Adnan Gucuk
I. Halil Bozkurt
M. Abdurrahim Imamoglu
Publikationsdatum
01.03.2009
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 1/2009
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-008-9408-x

Weitere Artikel der Ausgabe 1/2009

International Urology and Nephrology 1/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.